one8zero8 LLC Invests $2.97 Million in Stryker Corporation $SYK

one8zero8 LLC acquired a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 9,420 shares of the medical technology company’s stock, valued at approximately $2,966,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Brighton Jones LLC grew its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new position in shares of Stryker during the second quarter valued at about $205,000. Marshall Wace LLP raised its position in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new stake in shares of Stryker in the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC bought a new stake in shares of Stryker in the second quarter valued at about $253,000. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on SYK. Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. BTIG Research decreased their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. BMO Capital Markets started coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Up 2.7%

Shares of SYK opened at $340.20 on Thursday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $326.19 and a two-hundred day moving average price of $332.95. The stock has a market cap of $130.49 billion, a price-to-earnings ratio of 35.25, a P/E/G ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 315,370 shares of company stock worth $98,463,501 over the last three months. 4.60% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.